Global Multiple Myeloma Market

1. Global Multiple Myeloma Market Size, Share, Growth Analysis, By Therapy by Drug type by Distribution channel- Industry Forecast 2023-2030 Global Multiple Myeloma Market Insights Global Multiple Myeloma Market size was valued at USD 23.53 billion in 2021 and is poised to grow from USD 25.06 billion in 2022 to USD 44.17 billion by 2030, growing at a CAGR of 6.5% in the forecast period (2023-2030). Multiple myeloma is a critical type of blood cancer that mostly targets plasma cells. It is an uncommon form of cancer. The number of diagnoses among patients is rising as a result of growing awareness of disease symptoms. As a result, several potentially blockbuster medications were introduced, and the treatment expertise of the leading Multiple Myeloma Market competitors increased. As per the Globocan 2020 information sheet,

2. there were an expected 19,292,789 new cancer cases, with about 9,958,133 cancer-related deaths. Furthermore, the International Agency for Research on Cancer (IARC) predicts that by 2040, the worldwide incidence of cancer will have increased to 27.5 million new cases and 16.3 million deaths. In the entire world, men are around 1.5 times more likely to have it than women. Although no single risk factor has been linked to multiple myeloma, suggested underlying causes include differences in health-risk behaviors like smoking and alcohol consumption as well as higher rates of obesity among males. The disease is more prevalent among the age group of older adults with median age i.e., between the age range 55 to 65 years. Global Multiple Myeloma Market Segmental Analysis Global multiple myeloma market is segmented by Therapy, Drug Type, Distribution Channel and Region. On the basis of therapy, the Multiple Myeloma Market is segmented into targeted therapy, biologic therapy, chemotherapy, others. On the basis of drug type, the Multiple Myeloma Market is segmented into immunomodulatory drugs, proteasome inhibitors, histone deacetylase inhibitors, monoclonal antibody drugs, steroids, and others. On the basis of Distribution channels, the Multiple Myeloma Market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. On the basis of Region, the Global Multiple myeloma market is categorized into North America, Europe, Asia-Pacific, South America, and MEA. Multiple Myeloma Market Analysis by Therapy On the basis of therapy, the Multiple Myeloma Market is segmented into targeted therapy, biologic therapy, chemotherapy, and others. Among

3. these, targeted therapy and chemotherapy are the most common types of treatments followed in any type of cancerdue to the effectiveness and accuracy of these treatments. Biologic therapy is preferred in trace percentage due to its high cost of treatment. Get a complete overview of Multiple Myeloma Market https://www.skyquestt.com/report/multiple-myeloma- market Multiple Myeloma Market Top Players Company Profiles •Sanofi •Novartis AG •Takeda Pharmaceutical Company Limited •Celgene Corporation (a subsidiary of Bristol-Myers Squibb) •Amgen Inc. •Johnson & Johnson •AbbVie Inc. •GlaxoSmithKline plc •Pfizer Inc. •Janssen Biotech, Inc. (a subsidiary of Johnson & Johnson) •Bristol-Myers Squibb Company •Merck & Co., Inc. •Onyx Pharmaceuticals (a subsidiary of Amgen Inc.) •Millennium Pharmaceuticals (a subsidiary of Takeda Pharmaceutical Company Limited) •Spectrum Pharmaceuticals, Inc. •Karyopharm Therapeutics Inc. •Genmab A/S •Servier Pharmaceuticals LLC •AbbVie Biotechnology Ltd. (a subsidiary of AbbVie Inc.)

4. •Janssen-Cilag International N.V. (a subsidiary of Johnson & Johnson About Us: Sky Quest Technology is leading growth consulting firm providing market intelligence, commercialization, and technology services. It has 450+ happy clients globally. Address: 1 Apache Way, Westford, Massachusetts 01886 Phone: USA (+1) 617-230-0741 Email:sales@skyquestt.com Sky Quest